Sponsor: NOVONORDISK
Randomised placebo-controlled study of the effect of weekly semaglutide 2.4 mg on the functioning and symptoms of patients with obesity-related heart failure with preserved ejection fraction
Study Team:
SI: drs. S.N. Voorrips, drs. MAT Vijver.
Projectmanager: Anja Branderhorst.
Research Nurse Zwanet; Margriet